Navigation Links
Assessing the most appropriate duration of dual antiplatelet therapy after coronary stenting
Date:8/30/2011

A randomised multicentre open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy is no better than six months DAPT in preventing adverse cardiac events.

However, the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) also found a consistently greater risk of haemorrhage in the 24-month dual therapy group according to all prespecified bleeding definitions, including the recently proposed Bleeding Academic Research Consortium classification. The need for transfusion was also increased in the longer treatment group.

The results, said investigator Dr Marco Valgimigli from the University Hospital of Ferrara, Italy, "question the validity of current guideline recommendations - which were based on registry data - that at least 12 months' dual antiplatelet therapy should be pursued after implantation of a drug-eluting stent.

"While we cannot exclude the possibility that a smaller than previously anticipated benefit may still exist in prolonging therapy with clopidogrel for several months after coronary stenting, our study clearly shows that the benefit to risk ratio of prolonged therapy has been over-emphasised."

The PRODIGY study was a 4-by-2 randomised, three-centre open-label clinical trial designed to assess the efficacy and safety of prolonged clopidogrel therapy for up to 24 months in all-comer patients receiving a balanced combination of drug-eluting stents (with various anti-intimal hyperplasia potency and belonging to both first and second generation). Patients were 18 years or older with chronic stable coronary artery disease or acute coronary syndromes, including non-ST-elevation and ST-elevation myocardial infarction.

More than 2000 patients scheduled for elective, urgent or emergency coronary angioplasty were randomly assigned in a 1:1:1:1 fashion to one of four stent types: everolimus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent or third-generation thin-strut bare metal stent. Randomisation to the four different types, said Dr Valgimigli, was justified by the different safety profile of each, which was meant to ensure that patients in the two main study groups (six versus 24 month dual antiplatelet therapy) received exactly the same stent types. At 30 days, patients in each stent group were then further randomised to either six or 24 months of dual antiplatelet treatment.

The primary objective of the study was to assess whether 24-month dual antiplatelet treatment, consisting of clopidogrel and aspirin after coronary stenting, was associated with a lower cumulative incidence of all-cause mortality, non-fatal myocardial infarction or cerebrovascular accident (the primary outcome) than six-month dual therapy.

Results showed that the cumulative risk of the primary outcome at two years was 10.1% with the 24-month treatment, and 10.0% with the six-month (HR 0.98; 95% CI 0.74-1.29; P=0.91). The individual risks of death, myocardial infarction, cerebrovascular accident or stent thrombosis did not differ between the two groups.

Among the patients receiving long-term dual antiplatelet therapy, there was a roughly two-fold greater risk of type 5, 3 or 2 bleeding events (HR 2.17, 95% CI 1.44-3.22; p=0.00018) as well as type 5 or 3 bleeding events (HR 1.78, 95% CI 1.02-3.13; p=0.037) according to the Bleeding Academic Research Consortium classification. The risks of TIMI-defined major bleeding and red blood cell transfusion were also increased in the 24-month clopidogrel group.

Commenting on the implications of the results, Dr Valgimigli said: " While a formal economic analysis will follow, the results of this study have important implications for heathcare expenditure - for this study shows that prolonging therapy with clopidogrel beyond six months is not only associated with no clinical benefit but also with a significant increase in actionable bleeding events requiring re-hospitalisations and multiple diagnostic and therapeutic resources."


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-633-473-335
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Assessing the science behind health claims
2. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
3. Assessing positive outcomes of phase III trials
4. Mortality rates are an unreliable metric for assessing hospital quality, study finds
5. Assessing the value of treatments to increase height
6. Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis
7. Inappropriate uses of frozen plasma
8. ESC supports appropriate use of nuclear imaging technology
9. Terminal cancer patients do not receive appropriate radiation therapy
10. Clinical decision support systems help control inappropriate medical imaging, study suggests
11. Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at present:, ... influenza shot seems to be having no effect on keeping this particularly bad strain of ... people around are coughing, sneezing, or sniffling , These facts are well-known ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. Mehryar ... official journal of The American Society for Aesthetic Plastic Surgery, in which he ... designed to correct drooping, retracted lower eyelids, which usually result from genetics, injury, ...
(Date:1/16/2017)... ... , ... One thing common to all types of cancer is that it’s ... The money spent screening for and treating cancer in the United States is estimated ... more than in any other country that has an advanced healthcare system, sometimes spending ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... New York, NY (PRWEB) , ... January 15, 2017 , ... ... growing strategic accounts in the United States for the asthma & allergy friendly mark. ... of America to independently test and identify consumer products to be more suitable for ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... -- The global pacemaker market is expected to reach ... report by Grand View Research, Inc. The heightening prevalence ... coverage is a key driving factor governing the growth ... devices are supporting the expansion of this vertical. ... growth rendering driver for this market. A death estimate ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek H. ... Law Firm, was recently appointed Liaison Counsel in ... for all Xarelto cases. In this role, Potts was ... and will actively assist the Court and Co Lead ... Milstein Adelman Jackson Fairchild & Wade ...
(Date:1/16/2017)...  Harrington Discovery Institute at University Hospitals in ... of The Harrington Project for Discovery & Development ... in collaboration with Alzheimer,s Drug Discovery Foundation (ADDF), ... Harrington Discovery Institute collaborations are ... into new medicines that will improve human health, ...
Breaking Medicine Technology: